Establishment Labs

Establishment Labs (NASDAQ: ESTA) is a global medical technology company founded in 2004, specializing in Femtech solutions for breast health, aesthetics, and reconstruction. The company operates within the medical devices and equipment sector, focusing on high-tech manufacturing and scientific innovation. With a workforce of 1,000-5,000 employees, the firm maintains a significant global footprint across three locations, delivering advanced surgical and wellness products to international markets.

The company’s product portfolio includes the Motiva Flora® tissue expander, a regulatory-approved device featuring an integrated port that is MRI conditional, specifically designed to improve outcomes in breast reconstruction following cancer treatment. Additionally, Establishment Labs offers Mia Femtech, a minimally invasive experience for breast harmony. These solutions are underpinned by a robust intellectual property strategy, comprising over 200 patent applications across 25 patent families and supported by more than 50 peer-reviewed scientific studies. The firm utilizes state-of-the-art manufacturing facilities to ensure high-quality production standards for its silicone-based implants and surgical tools.

Establishment Labs demonstrates strong market positioning through continuous innovation and strategic capital management. Meet Establishment Labs's team to understand the leadership driving these technological advancements. The company’s financial performance reflects its growth trajectory, with annual revenue reaching $229.6M. Explore financial highlights to review detailed metrics and funding history, including recent debt financing rounds from Oaktree. The firm remains committed to advancing patient safety and surgical outcomes through its specialized engineering and research initiatives.